Showing results (171-180 of 226) with videos related to

Sort By:
Pageof 23
Cancers|May 16, 2023
Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) BiobankArnaud Martel, Lauris Gastaud, Christelle Bonnetaud, et al.
Cancer Letters|March 9, 2023
Combined inhibition of polyamine metabolism and eIF5A hypusination suppresses colorectal cancer growth through a converging effect on MYC translationSonia Coni, Rosa Bordone, Devon Michael Ivy, et al.
ERJ Open Research|December 8, 2021
Salivary detection of COVID-19: clinical performance of oral sponge sampling for SARS-CoV-2 testingJacques Boutros, Jonathan Benzaquen, Charles Hugo Marquette, et al.
Oncogene|September 21, 2024
MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptationRosa Bordone, Devon Michael Ivy, Rodrigo D'Amico, et al.
Annales De Pathologie|April 24, 2012
[Setting up indicators in biobanking: why and how?]Véronique Hofman, Marie-Clotilde Gaziello, Christelle Bonnetaud, et al.
Endocrine-Related Cancer|July 23, 2011
Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?Sandra Lassalle, Véronique Hofman, Marius Ilie, et al.
Annales De Pathologie|December 17, 2013
[The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm: Sharing of experience]Kevin Washetine, Elodie Long, Véronique Hofman, et al.
Oncotarget|December 22, 2017
Optimization of <i>EGFR</i> mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancerMarius Ilie, Catherine Butori, Sandra Lassalle, et al.
Annals of Translational Medicine|August 5, 2021
A rapid near-patient RT-PCR test for suspected COVID-19: a study of the diagnostic accuracyPaul Hofman, Jacques Boutros, Didier Benchetrit, et al.
Haematologica|February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia modelsStuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Pageof 23